drugset / Trial / NCT06981325
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
Phase 2
Recruiting
34 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Regeneron Pharmaceuticals · collabSkin Cancer Center Minden, Department of Dermatology, Johannes-Wesling-Klinikum Minden · collabUniversität Duisburg-Essen · collab
NaSingle-groupOpen-labelTreatment
Summary
The study is an open-label, singel arm, prospective, multicenter phase II trial evaluating the efficacy and safety of Cemiplimab when applied as first-line therapy in patients with locally advanced basal cell carcinoma (BCC), which were not pretreated with hedgehog inhibitors (HHI).
Timeline
- Start
- 2025-08-07
- Primary completion
- 2028-10
- Completion
- 2029-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |